Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Dose-Response Study of the Efficacy and Safety of MEDI7352 in Subjects With Painful Diabetic Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Oct 2023
Price :
$35
*
At a glance
- Drugs MEDI 7352 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 22 Oct 2023 This study has been discontinued n Spain, according to European Clinical Trials Database record.
- 08 Sep 2023 Planned number of patients changed from 111 to 272.
- 06 Sep 2023 Status changed from active, no longer recruiting to completed.